FindTrial
Sign In

ModraDoc006/r

DRUG8 trials

Sponsors

Modra Pharmaceuticals, Modra Pharmaceuticals BV

Conditions

Advanced Solid TumoursAdvanced solid tumours advanced solid type of cancerCastration-resistant Prostate CancerImpaired Liver FunctionMetastatic Breast CancerProstate Cancer MetastaticRecurrent Breast CancerSolid Tumor, Adult

Phase 1

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer
CompletedNCT03136640
Modra PharmaceuticalsCastration-resistant Prostate Cancer
Start: 2017-04-26End: 2019-09-05Updated: 2021-10-19
Food Effect Study of ModraDoc006 in Combination With Ritonavir
CompletedNCT03147378
Modra PharmaceuticalsSolid Tumor, Adult
Start: 2017-05-10End: 2018-04-04Updated: 2021-10-19
Extended Use of ModraDoc006/r
CompletedNCT03150368
Modra PharmaceuticalsAdvanced Solid Tumours
Start: 2017-05-10End: 2019-05-16Updated: 2021-10-19
Oral Docetaxel in Patients With Normal or Impaired Liver Function
WithdrawnNCT05084456
Modra PharmaceuticalsImpaired Liver Function, Solid Tumor, Adult
Start: 2017-07-31End: 2020-04-30Updated: 2021-10-19
Absorption and Excretion of Oral Docetaxel
WithdrawnNCT05242926
Modra PharmaceuticalsSolid Tumor, Adult
Start: 2017-10-31End: 2018-06-30Updated: 2022-02-16

Phase 2

Safety of extended use of ModraDoc006/r in patients with advanced solid tumours
RecruitingNL-OMON45294
Modra Pharmaceuticals BVAdvanced solid tumours advanced solid type of cancer
Start: 2017-05-11Target: 200Updated: 2024-02-28
ModraDoc006/r in Patients With Breast Cancer
CompletedNCT03890744
Modra PharmaceuticalsMetastatic Breast Cancer, Recurrent Breast Cancer
Start: 2019-01-30End: 2020-11-09Updated: 2021-10-19
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
CompletedNCT04028388
Modra PharmaceuticalsCastration-resistant Prostate Cancer, Prostate Cancer Metastatic
Start: 2019-07-17End: 2021-11-29Updated: 2024-04-17

Related Papers

A phase 2 randomized study of oral docetaxel plus ritonavir (ModraDoc006/r) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-06-011 citations
Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2022-02-161 citations
Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours.
2021-03-2011 citations
Phase IIb trial of oral ModraDoc006/r as a tolerable and effective option in comparison with intravenous docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Journal of Clinical Oncology2021-02-201 citations
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
2021-01-192 citations
A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388).
Journal of Clinical Oncology2020-02-195 citations
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
Journal of Clinical Oncology2020-02-192 citations